Keywords: ph, iii, panretin, data, ind, filed, tse-424

Ph III Panretin Data, IND Filed For TSE-424

Article | 02 April 1998

Results from a Phase III trial of Ligand Pharmaceuticals' Panretingel (9-cis-retinoic acid) in Kaposi's sarcoma have demonstrated that 37.1% of patients ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Wyeth

Go to company listing

Related Drugs

Alitretinoin

Panretin

Go to drug listing